Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T19:21:30.465Z.
Calculation as of: 2026-10-06T19:21:30.465Z.
Quote observation: 2026-10-06T19:20:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 3e31615b66e5acc6c2b7b3f8a521ec69124b31f47383f0f9627e8176a83f275d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Definium Therapeutics, Inc.
Market Cap
$4.68B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.64B
EV/EBITDA Ratio
76.11x
TTM Avg
416.98x
3Y Avg
416.98x
5Y Avg
416.98x
Market Cap
$4.68B
EV/EBITDA Ratio
34.98x
TTM Avg
39.32x
3Y Avg
75.54x
5Y Avg
104.36x
Market Cap
$4.70B
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$4.65B
EV/EBITDA Ratio
13.97x
TTM Avg
13.23x
3Y Avg
15.13x
5Y Avg
17.95x
Market Cap
$4.78B
EV/EBITDA Ratio
N/A
TTM Avg
2239.52x
3Y Avg
2239.52x
5Y Avg
2239.52x
Market Cap
$4.46B
EV/EBITDA Ratio
8.91x
TTM Avg
11.30x
3Y Avg
25.94x
5Y Avg
24.40x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definium Therapeutics, Inc. (DFTX) | $4.68B | N/A | N/A | N/A | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.64B | 76.11x | 416.98x | 416.98x | 416.98x |
| LifeStance Health Group, Inc. (LFST)vs › | $4.68B | 34.98x | 39.32x | 75.54x | 104.36x |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.70B | N/A | N/A | N/A | N/A |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 13.97x | 13.23x | 15.13x | 17.95x |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.78B | N/A | 2239.52x | 2239.52x | 2239.52x |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.81B | N/A | N/A | N/A | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.46B | 8.91x | 11.30x | 25.94x | 24.40x |
| Erasca, Inc. (ERAS)vs › | $4.94B | N/A | N/A | N/A | N/A |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.41B | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
